Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  BioPharma  /  INSM - Insmed - Deel 15

BioPharma« Terug naar discussie overzicht

INSM - Insmed - Deel 15

Volgen
2.002 Posts
Pagina: «« 1 ... 96 97 98 99 100 101 »» | Laatste | Omlaag ↓
  3. [verwijderd] 17 januari 2008 22:01
    quote:

    marieke2 schreef:

    ohmygod

    Nog steeds vol frustraties, een emotonele belgger is een slechte belegger, dus hier niet meer afreageren graag. Je laat enkel merken dat je een bom geld verloren bent...

    Ja dahag, bespaard bedoel je als ik naar de koers van vandaag kijk.

    Maar je hebt gelijk, ik zal hier niet meer reageren.

    Groet,
    OMG

  5. [verwijderd] 18 januari 2008 16:22
    Leuk verhaaltje van Yahoo, mss door een iets te roze bril maar de potentie zoals beschreven is er natuurlijk wel. Als ik de markt en de bijbehorende bedragen zie wordt ik duizelig...

    -----------------------------------------------

    For some it's a pathway to near-term financial independence. Most folks, like myself, have a secure job that will lead to financial independence over 30 years or so. I invest with the expectation that it will shorten this time-frame substantially, and in the case of INSM, could bring financial independence in a very short time frame.
    For some it's a pathway to immense wealth. And why not? All we need is one indication to "hit" and INSM will be an overnight 10 bagger. If and when several avenues pan out, then the 100 fold potential becomes reality. How?

    MMD- 90,000+ patients in the US and EU with no treatment and nothing but Iplex in the pipeline. Phase 3 trial is just around the corner based on continued success. The science has unequivically backed the effectivenes of Iplex in this indie. Market opportunity: 90k*$40k= $3.6 billion

    HARS- 100,000+ patients in the US and EU that have insulin sensitivity, and can't use regular growth hormone therapy. Any moment for announcement of ph-3 enabling trial. Science unequivically backs efficacy. Market opp: 100k*$20k= $2 billion

    FOB- 10s of billions of biologics coming off patent. US economy in peril and needs lower costs for these. INSM is ready and able to meet the demand for lower-cost biologics.
    Market opportunity: 2-3 billion dollars

    INSM-18 Prostate Cancer: enough said

    IFGBP-3: Synthesis with major cancer treatments for a variety of cancers, and may handle many forms of cancer on its own.

    NAP500 licensed to NAPO pharma to go into Phase 2 diabetes testing in India and other potential metabolic conditions.

    -----------------------------------------------

    Nogmaals, leuk om te dromen en niet bedoeld als pump. Daar hebben we anderen voor...

    R.
    p.s. benieuwd waar we over 1 jaar staan.
  6. [verwijderd] 18 januari 2008 18:37
    INSM technical analysis ( jan 18th '08 ) chart for those not following it
    Compare the price range and graphs with the 60 cent levels last summer.

    www.xs4all.nl/~surg3on/INSM_TA_chart_...

    Keep note of RSI, Stochastics and macd on oversold levels.
    Does not mean it will pop back in a day, but those are good indicators when combines with fundamental analysis


    Good luck
  7. [verwijderd] 18 januari 2008 22:15
    Crack, waar blijft de partner? Waar blijft de ALS update?

    De ijzersterke steun was toch 0,69/0,70?

    Of heb je weer bijgekocht vandaag. Als ik al je berichten bij elkaar zoek dat je hebt bijgekocht moet je inmiddels wel op een megaverlies staan. Da's niet fijn en gun ik niemand, ook jou niet.

    Maar never fall in live with one stock.
    Oppassen dus.....

    Fijn weekend.

    Groet,
    OMG
  8. [verwijderd] 18 januari 2008 22:24
    ik sta inderdaad in het rood hier met huidige koers en koop niet veel meer bij omdat bij mij ook geen onbeperkte bronnen zijn, maar wel een goed betaalde baan

    boven de dollar dik in de plus, maar moet even avg rekenen met dollar verlies

    nog wat cash vrijgemaak elders en volgende week kijken waar ie stabilisseert..
    als je charts ziet was 0,70 eerdere weerstand vanaf 0,65
    dus volgende week kijken of ie daar stabiliseert

    en ja,,uitblijven nieuws is niet leuk op moment bij deze martkcondities, maar ik zit hem rustig uit, geen beren op het pad hier en data totnutoe gewoon positief
  9. [verwijderd] 20 januari 2008 22:11
    Re: INSM is OK at this Price- condasending superman 20-Jan-08 10:00 am The SP of Insmed is artificial.Your emotional prey is an easy target.

    90 cents was a good buy if those controlling the trading wanted it to be.The manufacturing plant alone is its value and a good regulatory hurdle was cleared with the initial approval.
    My rational thinking is that there is an agenda to the trading,and it has zero to do with "value"of the company.it has to do with control of the company.Unlike you I don't pretend to know the outcome and have often voiced my disappointment with the management.Because you are lucky(first days of Jan - the worst ever for the stock market) doesn't make you so smart.When the eventual resolution comes- say a offer for the company,your arguments will look shallow....rationally speaking of course
    Have a nice day
    Rating :
    (5 Ratings)You have rated

    ---------------------------------------
    zo denk ik er ook over, alhoewel ik eerder denk aan een indicatieverkoop van bv hars icm een fob deal

    maar dat is speculeren en we zien wel hoe het loopt
  11. sappas 22 januari 2008 14:14
    Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market
    Study Estimates Potential Myotonic Muscular Dystrophy Market Could be as High as $800 Million to $1.4 Billion

    RICHMOND, Va., Jan 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that a leading management consulting firm has completed a market assessment of the potential market for therapeutic treatments related to Myotonic Muscular Dystrophy (MMD), also known as dystrophia myotonica or Steinert's disease. The research was conducted on behalf of Insmed, which is currently conducting a Phase III enabling trial for its MMD product candidate, IPLEX(TM). Based on responses from neurologists interviewed, patients afflicted with MMD could number between 28,300 and 37,000 by 2010, and the total market for MMD treatments could be as high as between $800 million and $1.4 billion.

    MMD is an inherited disease characterized by prolonged muscle tensing (myotonia) where certain muscles are not able to relax after use. Muscular Dystrophy is diagnosed at the rate of 50,000 to 250,000 persons annually in the U.S., and MMD is the most common form of the disease. DM1, which occurs in approximately 98% of MMD cases, is caused by an excessive number of cytosine, thymine and guanine (CTG) repeats on Chromosome 19. Symptoms of MMD include muscle wasting, weakness, pain, endurance loss, cognitive impairment and gastro-intestinal dysfunction.

    There is currently no cure for the disease, and no specific treatment has been discovered to satisfactorily reverse or ameliorate the common symptoms associated with MMD. Current treatments for MMD are directed toward managing the clinical manifestations of the disease, such as drugs aimed at treating multiple symptoms with the intent of addressing the delayed muscle relaxation.

    "The results of this study highlight that the MMD patient population is under-served," said Steve Glover, President, Insmed Therapeutic Proteins. "We intend to continue executing on our regulatory strategy for IPLEX in MMD, which was recently granted Orphan Drug Designation by the FDA in an attempt to better serve this patient category. Our recently secured grant of approximately $2.1 million from the Muscular Dystrophy Association is expected to cover a substantial portion of the external costs associated with our 24-week Phase III enabling trial in MMD patients, and we are hopeful of making this important product candidate available to patients as quickly as possible."

    These interviews, seeking information about the current treatment of MMD, emerging treatments and trends and therapies via a blinded product profile, were conducted in physician settings ranging from individual practices to large multi-specialist group practices in rural, urban and academic environments in different locations in the U.S.

    About IPLEX(TM)

    IPLEX(TM) was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD). IPLEX(TM) (rhIGF-I/rhIGFBP-3), is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug is also being investigated for various other indications with unmet medical needs.

    About Insmed

    Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.

    Forward-Looking Statements

    This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    SOURCE Insmed Inc.

    www.insmed.com

    Copyright (C) 2008 PR Newswire. All rights reserved

    News Provided by COMTEX

    Groetjes,

    Sappas
  12. ludwig mack 22 januari 2008 17:29
    ja, leuk bericht, goed nieuws; de koers gaat ook omhoog:

    Last Trade: 0.74
    Trade Time: 11:11AM ET
    Change: 0.06 (8.82%)
    Prev Close: 0.68
    Open: 0.68
    Bid: 0.73 x 1000
    Ask: 0.75 x 10000
    1y Target Est: 2.00

    Day's Range: 0.66 - 0.75
    52wk Range: 0.56 - 1.65
    Volume: 131,125
    Avg Vol (3m): 746,684
    Market Cap: 90.15M
    P/E (ttm): N/A
    EPS (ttm): -0.35
    Div & Yield: N/A (N/A)

  14. [verwijderd] 22 januari 2008 22:56
    Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total investing experience. Our focus is to give investors the financial advantage necessary to sustain profits in all markets. Tuesday, January 22, 2008 we have added (NASDAQ:INSM) to our portfolio.

    The Maybach Financial Group www.maybachfinancial.com will be researching the above-mentioned companies for our members. Visit www.maybachfinancial.com for a complimentary subscription to the Maybach service and receive at no cost our "Special Report#1: The Pick of the Decade" No credit card or payment information is required.

    Voor wat het waard is.
  16. [verwijderd] 23 januari 2008 16:59
    quote:

    am schreef:

    Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total investing experience. Our focus is to give investors the financial advantage necessary to sustain profits in all markets. Tuesday, January 22, 2008 we have added (NASDAQ:INSM) to our portfolio.

    The Maybach Financial Group www.maybachfinancial.com will be researching the above-mentioned companies for our members. Visit www.maybachfinancial.com for a complimentary subscription to the Maybach service and receive at no cost our "Special Report#1: The Pick of the Decade" No credit card or payment information is required.

    Voor wat het waard is.
    iedere aandacht is altijd goed
    heb ze een mailtje gestuurd met aanbod informatie te geven
  19. [verwijderd] 24 januari 2008 14:07
    Press Release Source: Insmed Inc.

    Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
    Thursday January 24, 8:00 am ET
    Company Received $5.2 Million in Cost Recovery from EAP in 2007

    RICHMOND, Va., Jan. 24 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM - News), a developer of follow-on biologics and biopharmaceuticals, today provided an update on the IPLEX(TM) Expanded Access Program (EAP) in Italy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Since early 2007, the EAP has grown to include 15 physicians and approximately 70 subjects have been enrolled into the program. Additional subjects continue to be enrolled into the program. IPLEX(TM) appears to have been safe and well tolerated in the subject population to date and no individuals have dropped out of the study for reasons related to IPLEX(TM). The Company received cost recovery of $5.2 million for drug supplies for the full-year 2007.


    The study utilizes a Revised ALS Functional Rating Scale (ALSFRS) to monitor the progress of the subjects. The ALSFRS is used to determine a patient's capacity and independence in several functional activities including speech, salivation, swallowing, handwriting, cutting foods and handling utensils, dressing and hygiene, turning in bed, walking, climbing stairs, and respiratory function. The purpose of collecting this information is to help ensure safety and to gain an understanding as to whether IPLEX(TM) provides any benefit to these subjects.

    ALS, often referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle movement action progressively negatively affected, those patients in the later stage of the disease may become totally paralyzed. The ALS Association believes that 5,600 people in the U.S. are diagnosed with ALS annually, and an estimated 30,000 Americans suffer from the disease. Most ALS patients die within three to five years after onset of symptoms, according to the National Institute of Neurological Disorders and Stroke.

    "We are pleased with the progress of the EAP for IPLEX(TM) in Italy," said Geoffrey Allan Ph.D., Insmed's President and Chief Executive Officer. "Because this disease has few treatment options, the patients participating in this study are in desperate need of effective medicines. We look forward to continuing to work with Italian health authorities and clinicians to advance this important study and, in conjunction with them, will proceed with a thorough analysis of the data from this study at an appropriate point in the future."

2.002 Posts
Pagina: «« 1 ... 96 97 98 99 100 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
AMG Critical Materials N.V. 16,100 +0,82 +5,37%
FASTNED 17,580 +0,88 +5,27%
Air France-KLM 8,440 +0,28 +3,48%
UMG 24,120 +0,73 +3,12%
AZERION 1,526 +0,05 +3,11%
Brunel 8,650 +0,26 +3,10%
Pharming 0,717 +0,02 +2,21%
BAM 3,712 +0,08 +2,09%
JUST EAT TAKEAWAY 12,465 +0,25 +2,05%
ArcelorMittal 20,890 +0,38 +1,85%
Basic-Fit 22,460 +0,38 +1,72%
ADYEN NV 1.305,400 +20,80 +1,62%
ALLFUNDS GROUP 5,340 +0,09 +1,62%
Accsys 0,646 +0,01 +1,57%
TKH 36,880 +0,56 +1,54%
SIGNIFY NV 21,260 +0,32 +1,53%
Philips Koninklijke 28,090 +0,39 +1,41%
ABN AMRO BANK N.V. 16,435 +0,22 +1,39%
Akzo Nobel 58,180 +0,74 +1,29%
Aperam 24,280 +0,30 +1,25%
CM.COM 6,550 +0,08 +1,24%
TomTom 4,914 +0,06 +1,24%
Flow Traders 18,470 +0,21 +1,15%
Nedap N.V. 57,400 +0,60 +1,06%
Kendrion 12,060 +0,12 +1,01%
ING 16,456 +0,16 +0,97%
CTP 16,740 +0,16 +0,97%
ASCX 1.195,15 +11,33 +0,96%
SHELL PLC 30,675 +0,28 +0,92%
AMX 896,29 +7,74 +0,87%
Corbion 23,840 +0,20 +0,85%
Vopak 42,920 +0,36 +0,85%
Van Lanschot Kempen NV 41,850 +0,35 +0,84%
PostNL 1,205 +0,01 +0,84%
Alfen N.V. 12,165 +0,10 +0,83%
AALBERTS NV 34,280 +0,28 +0,82%
Galapagos 27,440 +0,22 +0,81%
PROSUS 32,510 +0,26 +0,81%
Sif Holding 12,680 +0,10 +0,79%
Eurocommercial Properties 25,600 +0,20 +0,79%
EXOR NV 98,400 +0,75 +0,77%
Sligro 13,160 +0,10 +0,77%
NSI 21,050 +0,15 +0,72%
INPOST 17,200 +0,12 +0,70%
Fugro 20,800 +0,14 +0,68%
SBM Offshore 16,410 +0,11 +0,67%
IMCD 157,000 +1,00 +0,64%
HEIJMANS KON 23,700 +0,15 +0,64%
AEX 901,44 +5,69 +0,64%
RANDSTAD NV 42,860 +0,26 +0,61%
Wolters Kluwer 158,550 +0,90 +0,57%
ASMI 570,600 +3,00 +0,53%
BESI 111,800 +0,55 +0,49%
Ahold Delhaize 31,130 +0,14 +0,45%
Wereldhave 15,000 +0,06 +0,40%
RELX 43,340 +0,16 +0,37%
ASML 722,300 +2,40 +0,33%
KPN 3,743 +0,01 +0,32%
Heineken 82,220 +0,26 +0,32%
Arcadis 65,150 +0,20 +0,31%
B&S Group SA 4,620 +0,01 +0,22%
ACOMO 17,400 +0,02 +0,12%
Aegon 5,440 +0,01 +0,11%
ASR Nederland 43,460 0,00 0,00%
EBUSCO HOLDING 0,812 0,00 0,00%
RENEWI 7,600 0,00 0,00%
Vastned 23,950 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
NX FILTRATION 4,650 -0,09 -1,90%
Avantium 1,892 -0,03 -1,77%
DSM FIRMENICH AG 118,450 -1,95 -1,62%
WDP 24,600 -0,14 -0,57%
THEON INTERNAT 11,260 -0,06 -0,53%
UNILEVER PLC 58,600 -0,14 -0,24%
Fagron 18,880 -0,04 -0,21%
JDE PEET'S 20,400 -0,04 -0,20%
ForFarmers 3,185 0,00 -0,16%
NN Group 44,650 -0,04 -0,09%
OCI 26,840 -0,01 -0,04%
vlag naam koers verschil relatief verschil
AEX 901,32 +5,57 +0,62%
AEX GR 3.519,07 +18,73 +0,54%
Germany40^ 18.718,30 +85,19 +0,46%
FTSE 100 8.339,20 +60,76 +0,73%
EURO50 4.857,21 +9,10 +0,19%
US30^ 41.715,80 +92,20 +0,22%
Nasd100^ 19.520,60 +101,40 +0,52%
US500^ 5.651,50 +17,73 +0,31%
Japan225^ 36.481,40 -205,70 -0,56%
VD-NEW 15,27 +0,64 +4,40%
#/^ Index indications calculated real time, zie disclaimer